ONE of the country’s leading life science specialists has joined the Northern Health Science Alliance (NHSA) to head up its corporate team.

Keith Miller, who joins NHSA as Head of Corporate Engagement, has held a number of senior roles across the North’s life sciences sector including as the first life science specialist for the Northern Powerhouse. His other roles encompass organisations from Astra Zeneca and Alderley Park to Midas, Manchester’s Inward Investment and Development Agency.

Professor David Burn, chair of the NHSA said: “We are delighted to announce that Keith Miller has joined the Northern Health Science Alliance as Head of Corporate Engagement.

“Keith has a wealth of experience in both public and private sectors. His unique experience makes him perfectly-placed to lead the NHSA’s corporate engagement and we are thrilled to have him on-board.”

Keith is passionate about supporting inward investment and research collaborations into the UK and the North of England in particular. He has a wide range of experience in both public and private sector roles.

He said: “Having worked with the NHSA on a number of occasions I am excited to take this opportunity to head their excellent work taking the North’s health science expertise to a global audience and developing its inward investment opportunity.”

Most recently Keith has been consulting as a life science specialist for Alderley Park to support the rapid growth and development of an innovation cluster at the UK’s largest single Bioscience Site.

Prior to that Keith was the first life science specialist for UK Department for International Trade to be assigned to the Northern Powerhouse and before that Keith led the life science sector for MIDAS, (Manchester’s Inward Investment and Development Agency)

He has enjoyed a broad and varied commercial career in the pharmaceutical and dental industries industry, most recently for AZ, where he led commercial teams focused on the early commercial interface with R&D. Keith’s teams provided the commercial input into the pre-phase II respiratory portfolio and commercial due diligence on licensing and acquisitions in the area.

Prior to that Keith was based in the US leading the emerging Neuroscience commercial portfolio teams for AZ.

In addition to front commercial and strategy roles Keith has also worked as a Pharma industry health economist and as a commercial leader and forecasting director in the manufacturing supply chain.

Keith has a BSc in Pharmacology and an AKC from King’s College London and an MBA from Henley Management College. Keith is co-author of a number of health economic publications.

In addition to his work for the NHSA, Keith is retained as Director of Strategic Alliances Europe for Molecular Pathology Laboratory Network Inc.

ENDS